Nitromist

prophylaxis of Angina pectoris, Congestive Heart Failure, Chest Pain + 10 more
Treatment
15 Active Studies for Nitromist

What is Nitromist

NitroglycerinThe Generic name of this drug
Treatment SummaryNitroglycerin is a special medication used to treat chest pain, high blood pressure and anal fissures. It comes in different forms - spray, tablets, intravenous, extended-release tablets, and an ointment. The ointment form was approved by the FDA in 1955. It is currently manufactured by Pfizer and other companies, depending on the dosage form.
Nitroglycerinis the brand name
image of different drug pills on a surface
Nitromist Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Nitroglycerin
Nitroglycerin
1981
182

Effectiveness

How Nitromist Affects PatientsNitroglycerin helps to relax the blood vessels, increasing blood flow to the heart and decreasing the amount of work the heart has to do. Nitroglycerin can also stop spasms in the coronary arteries, reducing the pressure in the arteries and lowering the blood pressure. However, taking nitroglycerin for too long can cause its effects to wear off, meaning it won't work as well as it used to. This may be due to an enzyme in the body being affected, and can lead to pro-oxidant effects, weak blood vessels, and an increased sensitivity to substances that cause vasoconstriction.
How Nitromist works in the bodyNitroglycerin works in the body to relax the muscles in blood vessels. It does this by turning into nitric oxide, a chemical that triggers the muscle relaxation. This leads to more space in the vessels, allowing more blood to flow and reducing pressure. Nitric oxide also activates a cascade of other chemicals that encourage relaxation. In addition, nitric oxide may also target natriuretic peptide receptors to further relax the muscles.

When to interrupt dosage

Condition
Dosage
Administration
Congestive Heart Failure
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
prophylaxis of Angina pectoris
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Chest Pain
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Coronary Disease
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Anal Fissure
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
nitroglycerin
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Angina Pectoris
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Hypotension
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
insufficient response to beta-blockers
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Hypertensive disease
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
induction of Intraoperative Hypotension
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Pain
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Myocardial Infarction
, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2
, Transdermal, Patch, Patch - Transdermal, Topical, Ointment, Ointment - Topical, Oral, Capsule, Capsule - Oral, Sublingual, Tablet - Sublingual, Tablet, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered, Spray, metered - Oral, Ointment - Rectal, Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Intravenous, Injection, solution, Injection, solution - Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Transmucosal, Aerosol, spray, Aerosol, spray - Transmucosal, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

Warnings

Nitromist has eleven contraindications, therefore it should not be used when struggling with any of the conditions outlined in the following table.Nitromist Contraindications
Condition
Risk Level
Notes
Cardiac Tamponade
Do Not Combine
Pulse Frequency
Do Not Combine
Hypovolemic Shock
Do Not Combine
Anemia
Do Not Combine
Pick Disease of Heart
Do Not Combine
Pulse Frequency
Do Not Combine
Acute Circulatory Failure
Do Not Combine
Intracranial Hypertension
Do Not Combine
Cardiomyopathy, Restrictive
Do Not Combine
Myocardial Infarction
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Nitroglycerin may interact with Pulse Frequency
There are 20 known major drug interactions with Nitromist.
Common Nitromist Drug Interactions
Drug Name
Risk Level
Description
Amediplase
Major
The therapeutic efficacy of Amediplase can be decreased when used in combination with Nitroglycerin.
Amifostine
Major
Nitroglycerin may increase the hypotensive activities of Amifostine.
Desmoteplase
Major
The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Nitroglycerin.
Reteplase
Major
The therapeutic efficacy of Reteplase can be decreased when used in combination with Nitroglycerin.
Riociguat
Major
Nitroglycerin may increase the hypotensive activities of Riociguat.
Nitromist Toxicity & Overdose RiskThe toxic dose of nitroglycerin in rats is 105 mg/kg if taken orally and 23.2 mg/kg if taken intravenously. Overdosing on nitroglycerin can cause severe low blood pressure, headache, dizziness, palpitations, flushing and cold skin, nausea, vomiting, difficulty breathing, slow pulse, confusion, paralysis, seizures, and possibly death. Methemoglobinemia, a rare side effect of nitroglycerin, can be treated with methylene blue unless the patient has a known G-6-PD deficiency. There is no known antidote for nitroglycerin overdose
image of a doctor in a lab doing drug, clinical research

Nitromist Novel Uses: Which Conditions Have a Clinical Trial Featuring Nitromist?

38 active studies are currently investigating the potential of Nitromist to prophylactically treat Gastroesophageal variceal hemorrhage, Hypotension and Congestive Heart Failure.
Condition
Clinical Trials
Trial Phases
Coronary Disease
1 Actively Recruiting
Not Applicable
Congestive Heart Failure
11 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Pain
0 Actively Recruiting
prophylaxis of Angina pectoris
0 Actively Recruiting
Hypertensive disease
0 Actively Recruiting
induction of Intraoperative Hypotension
0 Actively Recruiting
Chest Pain
2 Actively Recruiting
Not Applicable, Phase 2, Phase 3
Anal Fissure
1 Actively Recruiting
Phase 1
Hypotension
0 Actively Recruiting
insufficient response to beta-blockers
0 Actively Recruiting
Angina Pectoris
0 Actively Recruiting
Myocardial Infarction
0 Actively Recruiting
nitroglycerin
0 Actively Recruiting

Nitromist Reviews: What are patients saying about Nitromist?

5Patient Review
7/6/2011
Nitromist for Angina
This medication has a long shelf life and is fast acting. I haven't found anything better on the market.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nitromist

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is NitroMist used for?

"NitroMist is used to treat or prevent attacks of chest pain by widening blood vessels, which increases blood flow and oxygen to the heart."

Answered by AI

Can you take too much nitroglycerin?

"If you take too much of this drug, you could have dangerous levels of it in your body. An overdose of this drug can cause throbbing headaches and confusion."

Answered by AI

What does nitroglycerin treat?

"Nitroglycerin sublingual tablets work by relaxing blood vessels and increasing blood flow to the heart, which helps to prevent or relieve episodes of angina. The tablets are typically used before activities that may trigger an episode of chest pain, so that the angina can be prevented before it starts."

Answered by AI

What is lingual aerosol?

"Nitrolingual Pumpspray is used to widen blood vessels and improve blood flow in order to prevent chest pain."

Answered by AI

Clinical Trials for Nitromist

Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA
Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.
Waitlist Available
Has No Placebo
Virginia Commonwealth UniversityAarti Sarwal
Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.
Recruiting
Has No Placebo
Ronald Reagan UCLA Medical Center
Have you considered Nitromist clinical trials? We made a collection of clinical trials featuring Nitromist, we think they might fit your search criteria.Go to Trials
Image of University of Tennessee Medical Center in Knoxville, United States.

Pharmacy Intervention for Medication Adherence

18+
All Sexes
Knoxville, TN
Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.
Recruiting
Senior-friendly
University of Tennessee Medical Center (+1 Sites)Satya Surbhi, PhD
Image of Brigham and Women's Hospital in Boston, United States.

Care Transitions App for Multiple Chronic Conditions

18+
All Sexes
Boston, MA
The objective of this study is to widely implement and evaluate the Care Transitions App in a randomized controlled trial. The app the investigators designed for patients with multiple chronic conditions has four envisioned modules: 1) falls-reduction content, 2) a digital post-discharge transitional care plan (e.g., after hospital care plan, including education, medications, follow-up appointments, warning signs to watch for, nutrition, and other care plan activities), 3) a new module for patients with MCC (diabetes, congestive heart failure, and chronic kidney disease) including condition-specific post-discharge care plans with relevant symptom management activities, 4) a new post-discharge report module which summarizes key care transition findings and allows for patients to enter notes and questions for their providers and their own goals for recovery.
Recruiting
Has No Placebo
Brigham and Women's HospitalLipika Samal, MD, MPH
Image of Saint Luke's Hospital of Kansas City in Kansas City, United States.

Remote Patient Monitoring for Heart Failure

18 - 80
All Sexes
Kansas City, KS
Previous research has investigated the use of remote patient monitoring in various clinical contexts, however there has not been a clinical trial examining use of the VitalCare platform for ambulatory management of heart failure. This trial will serve as a pilot study examining the feasibility of use of the VitalCare platform for ambulatory heart failure management and examine the effect of remote patient monitoring on patient engagement. To the investigators' knowledge, this will be the first study examining the effect of remote patient monitoring with the VitalCare platform on heart failure clinical outcomes, such as hospitalization for heart failure exacerbations and emergency room visits for heart failure.
Waitlist Available
Has No Placebo
Saint Luke's Hospital of Kansas City (+3 Sites)
Have you considered Nitromist clinical trials? We made a collection of clinical trials featuring Nitromist, we think they might fit your search criteria.Go to Trials
Have you considered Nitromist clinical trials? We made a collection of clinical trials featuring Nitromist, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security